Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.63 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | GUSB | P08236 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579908 | 0.88 | PARP1 (0.61) | PARP1TNKSTNKS2DHODHPARP2 | |
| SCHEMBL15958954 | 0.87 | PARP1 (0.62) | PARP1TNKSGUSBTNKS2DHODH | |
| SCHEMBL6809996 | 0.86 | PKN1 (0.63) | PARP1DHODHPARP2CHEK2PLK4 | |
| SCHEMBL7583436 | 0.84 | PARP1 (0.66) | PARP1TNKSTNKS2DHODHPARP2 | |
| SCHEMBL7138977 | 0.83 | PARP1 (0.50) | PARP1DHODHPARP2 | |
| Guanidine SCHEMBL8692697 | 0.81 | PARP1 (0.52) | PARP1TNKSGUSBTNKS2DHODH | |
| SCHEMBL3585144 | 0.81 | PARP1 (0.64) | PARP1DHODHPLK4MAP4K4PIM1 | |
| SCHEMBL6805361 | 0.81 | PDPK1 (0.43) | PARP1DHODHPARP2CHEK2PLK4 | |
| SCHEMBL29696369 | 0.80 | NPC1 (0.53) | PARP1DHODHCSNK1D | |
| SCHEMBL6806964 | 0.80 | PKN1 (0.65) | PARP1DHODHPARP2CHEK2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237762-A1 | USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-07-30 | — | — | US | claimed |
| US-20180000822-A1 | Use of RNAI Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer | THE UNIVERSITY OF SHEFFIELD (GB) | 2018-01-04 | — | — | US | claimed |
| EP-1649017-B1 | USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | UNIV SHEFFIELD (GB) | 2011-07-13 | — | — | EP | claimed |
| US-20070179160-A1 | derivatives of tricyclic lactam indoles and tricyclic lactam benzimidazoles; poly (ADP-ribose) polymerase (PARP) inhibitors; breast cancer, cancers caused by genetic defect in a gene; side effects reduction by not administering as a combination therapy; low doses; antiapoptosis; BRCA1 or BRCA2 expression | THE UNIVERSITY OF SHEFFIELD (GB) | 2007-08-02 | — | — | US | claimed |
| US-20230065522-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220062286-A1 | USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-03-03 | — | — | US | disclosed |
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE LONDON (GB) | 2021-02-18 | — | — | US | disclosed |
| US-20200360538-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200360538-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-11-19 | — | — | US | disclosed |
| US-10799501-B2 | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L | KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20200237762-A1 | USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20160208339-A1 | BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS | KING'S COLLEGE LONDON (GB) | 2016-07-21 | — | — | US | disclosed |
| WO-2015040378-A1 | BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS | KING'S COLLEGE LONDON (GB) | 2015-03-26 | — | — | WO | disclosed |
| US-8859562-B2 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer | THE UNIVERSITY OF SHEFFIELD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-20140051737-A1 | METHODS FOR THE TREATMENT AND DIAGNOSTIC OF PULMONARY ARTERIAL HYPERTENSION | UNIVERSITE LAVAL (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | The Institute of Cancer Reseach | 2012-05-31 | — | — | US | disclosed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | disclosed |
| CN-101380297-A | Compound platinum medicine sustained-release agent | JINAN SHUAIHUA PHARMACEUTICAL (CN) | 2009-03-11 | — | — | CN | disclosed |
| US-20070179160-A1 | derivatives of tricyclic lactam indoles and tricyclic lactam benzimidazoles; poly (ADP-ribose) polymerase (PARP) inhibitors; breast cancer, cancers caused by genetic defect in a gene; side effects reduction by not administering as a combination therapy; low doses; antiapoptosis; BRCA1 or BRCA2 expression | THE UNIVERSITY OF SHEFFIELD (GB) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | MRE11, ERCC4, PARP2 | PARP1 7/4885TNKS 82/4885GUSB 2508/4885 |
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | PARP3, PARP11, GSK3A | PARP1 5/4885TNKS 33/4885GUSB 3666/4885 |
| US-20230065522-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | PARP2, PARP1, PARP3 | PARP1 2/4885TNKS 41/4885GUSB 2095/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | PARP1 1298/4885TNKS 1658/4885GUSB 582/4885 |
| US-10799501-B2 | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L | PARP3, PARP11, GSK3A | PARP1 5/4885TNKS 33/4885GUSB 3666/4885 |
| US-20140051737-A1 | METHODS FOR THE TREATMENT AND DIAGNOSTIC OF PULMONARY ARTERIAL HYPERTENSION | PARP1, PARP11, PARP3 | PARP1 1/4885TNKS 31/4885GUSB 1803/4885 |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | CHEK1, CHEK2, PARP1 | PARP1 3/4885TNKS 6/4885GUSB 3066/4885 |
| US-20200360538-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | PARP2, PARP1, PARP3 | PARP1 2/4885TNKS 41/4885GUSB 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.